As mention above due to oncogenic role of miR-182-5p and their effect on CEBPα as potentially anti-proliferative in myeloid cells, therapeutic strategies using inhibition of miR-182 in APL and other malignant disorders may be useful. The gene discussed is CEBPA; the disease is acute promyelocytic leukemia.